Drug Profile


Alternative Names: Isoniazid/pyrazinamide/rifampicin/ethambutol; Myrin- p Forte; Pyrazinamide/rifampicin/ethambutol/isoniazid; Rifampicin/ethambutol/isoniazid/pyrazinamide

Latest Information Update: 06 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Antituberculars; Ethylenediamines; Hydrazines; Isonicotinic acids; Pyrazines; Rifamycins
  • Mechanism of Action Cell wall inhibitors; DNA-directed RNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Tuberculosis

Most Recent Events

  • 06 Sep 2017 No development reported - Phase-I for Tuberculosis in Singapore (PO)
  • 12 Aug 2015 Launched for Tuberculosis in Philippines (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top